JPWO2023060242A5 - - Google Patents

Info

Publication number
JPWO2023060242A5
JPWO2023060242A5 JP2024520927A JP2024520927A JPWO2023060242A5 JP WO2023060242 A5 JPWO2023060242 A5 JP WO2023060242A5 JP 2024520927 A JP2024520927 A JP 2024520927A JP 2024520927 A JP2024520927 A JP 2024520927A JP WO2023060242 A5 JPWO2023060242 A5 JP WO2023060242A5
Authority
JP
Japan
Prior art keywords
fold
prodrug
inducible
composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538707A5 (https=
JP2024538707A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077772 external-priority patent/WO2023060242A1/en
Publication of JP2024538707A publication Critical patent/JP2024538707A/ja
Publication of JPWO2023060242A5 publication Critical patent/JPWO2023060242A5/ja
Publication of JP2024538707A5 publication Critical patent/JP2024538707A5/ja
Pending legal-status Critical Current

Links

JP2024520927A 2021-10-08 2022-10-07 Ｉｌ－２プロドラッグ Pending JP2024538707A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163253964P 2021-10-08 2021-10-08
US63/253,964 2021-10-08
US202163290941P 2021-12-17 2021-12-17
US63/290,941 2021-12-17
US202263328524P 2022-04-07 2022-04-07
US63/328,524 2022-04-07
PCT/US2022/077772 WO2023060242A1 (en) 2021-10-08 2022-10-07 Il-2 prodrug

Publications (3)

Publication Number Publication Date
JP2024538707A JP2024538707A (ja) 2024-10-23
JPWO2023060242A5 true JPWO2023060242A5 (https=) 2025-09-24
JP2024538707A5 JP2024538707A5 (https=) 2025-09-24

Family

ID=83978868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520927A Pending JP2024538707A (ja) 2021-10-08 2022-10-07 Ｉｌ－２プロドラッグ

Country Status (6)

Country Link
US (1) US20240374687A1 (https=)
EP (1) EP4412712A1 (https=)
JP (1) JP2024538707A (https=)
KR (1) KR20240082401A (https=)
CA (1) CA3233893A1 (https=)
WO (1) WO2023060242A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250977A1 (en) * 2024-05-31 2025-12-04 Werewolf Therapeutics, Inc. Cancer therapy using il-2 prodrug
WO2026072455A1 (en) * 2024-09-26 2026-04-02 Werewolf Therapeutics, Inc. Single domain human serum albumin antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Similar Documents

Publication Publication Date Title
Xue et al. Next-generation cytokines for cancer immunotherapy
Conlon et al. Cytokines in the treatment of cancer
CA2497552C (en) Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
Zhang et al. Low-dose IL-2 therapy in autoimmune diseases: An update review
Kim et al. IL-7 and IL-15: biology and roles in T-Cell immunity in health and disease
Huang et al. The broad immunomodulatory effects of IL-7 and its application in vaccines
Kurosawa et al. Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes
Zhou et al. The application of Interleukin-2 family cytokines in tumor immunotherapy research
CA2510180A1 (en) Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
IE912486A1 (en) Adoptive immunotherapy with interleukin-7
ES2342529B1 (es) Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
US20240374687A1 (en) Il-2 prodrug
Yoshimoto et al. Interleukins and cancer immunotherapy
Konjević et al. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK-and T-cell subsets in patients with metastatic melanoma treated with interferon-α and DTIC
JPWO2023060242A5 (https=)
Eisenthal et al. The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Eisenthal et al. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Baxevanis et al. Induction of lymphokine-activated killer activity in mice by prothymosin α
Punnonen et al. Cytokine therapeutics in cancer immunotherapy: design and development
Margolin et al. Cytokines in the treatment of cancer
Baxevanis et al. Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes
Damle et al. Interleukin‐2 activated human killer lymphocytes: Lack of involvement of interferon in the development of IL‐2‐activated killer lymphocytes
Vlk et al. CLINICAL INEFFECTIVENESS OF IL-2 AND/OR IFN ALPHA ADMINISTRATION AFTER AUTOLOGOUS PBSC TRANSPLANTATION IN PEDIATRIC
Lim et al. Tumor cell clone expressing the membrane-bound form of IL-12p35 subunit stimulates antitumor immune responses dominated by CD8+ T cells
Lim et al. Antitumor effects of a tumor cell vaccine expressing a membrane-bound form of the IL-12 p35 subunit